Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Wanbury Ltd. Share Price
Day's Range
Day's Range
Low
₹272.40
High
₹291.35
Price Summary
| Previous Close | ₹284.45 |
|---|---|
| Day's Range | ₹272.40 - ₹291.35 |
| Open | ₹274.35 |
| 52 Week Range | ₹161.50 - ₹315.20 |
| Volume | 1,56,944 |
| Market Cap | ₹0.00 |
| Previous Close | ₹284.20 |
|---|---|
| Day's Range | ₹271.45 - ₹291.10 |
| Open | ₹271.45 |
| 52 Week Range | ₹162.00 - ₹316.60 |
| Volume | 12,035 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 446.43 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 22.29 |
| TTM EPS (₹) | 12.30 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 14.28 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
| Trade Value ( ₹ in Lacs) | 34.20 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 22.29 |
| TTM EPS (₹) | 12.30 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 14.28 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 5995.14 | 1720.0 |
| Expenses | N/A | N/A |
| PBT | 295.51 | 190.54 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 305.3 | 202.56 |
About Wanbury Ltd.
| Founded | 1988 |
|---|---|
| NSE Symbol | WANBURY |
Latest News
FDC informs about disclosure
Artemis Medicare Services informs about trading window closure
Vivo Bio Tech informs about closure of trading window
Mercury Laboratories informs about newspaper advertisement
Sudeep Pharma informs about closure of trading window
Pursuant to the Code of Conduct on Prevention of Insider Trading of the Company and SEBI (Prohibition of Insider Trading) Regulations, 2015, Sudeep Pharma has informed that the trading window for dealing in the securities of the Company shall be closed for designated persons from Wednesday, 1st July 2026 and shall remain closed till 48 hours after the declaration of the un-audited financial results of the Company for quarter ending on 30th June 2026 and other matters, if any. Accordingly, all Designated Persons and their immediate relatives, directly or indirectly, are prohibited to deal in the securities of the Company during this period. The date of the meeting of the Board of directors to approve the un-audited financial results of the company for the aforementioned quarter, shall be informed to the stock exchanges in due course.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wanbury Ltd. is ₹284.45 as of 2026-06-29.
The market capitalisation of Wanbury Ltd. is ₹958.04 as of 2026-06-25.
The 1-year return of Wanbury Ltd. is 0.75% as of 2026-06-29.
The P/E ratio of Wanbury Ltd. is 25.19 as of 2026-06-29.
The 52-week high and low of Wanbury Ltd. are ₹315.20 and ₹161.50, respectively, as of 2026-06-29.
People Also Ask
Wanbury Ltd. was originally incorporated as Pearl Organics Limited in August 1988. The company adopted the name Wanbury Limited in September 2004. This change reflected its transition into a pharmaceutical manufacturing business with a broader operational scope and growing presence in domestic and international markets.
Wanbury Ltd. is a publicly listed company whose equity shares are traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Being listed on these exchanges allows participation from both retail and institutional investors and ensures compliance with regulatory disclosure and governance standards.
Wanbury Ltd. generates revenue through the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company produces and exports medicines used in therapeutic areas such as diabetes management. Its operations include production, research, and distribution across multiple regulated and semi-regulated global markets.
Pradeep Patni serves as the Chief Executive Officer of Wanbury Ltd., having assumed the role in August 2024. He is responsible for overseeing the company’s strategic direction and operations, working alongside Mohan Kumar Rayana, who is the Promoter and Whole-Time Director involved in leadership and governance functions.
Wanbury Ltd. is a pharmaceutical company engaged in the development and manufacturing of APIs and formulations. With over three decades of experience, it operates integrated facilities that support research and production. The company supplies its products to domestic and international markets, including regulated regions across various therapeutic categories.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
